Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22...
Company Ends Quarter in Strongest Financial Condition Ever VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM...
VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive Officer, will...
VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company and a developer of vaccines...
Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion VIENNA, Va., Jan. 13...
Facility Is Also Expected to Generate Revenue Through Contract Manufacturing VIENNA, Va., Jan. 11 /PRNewswire-FirstCall/ -- CEL-SCI Corporation...
VIENNA, Va., Dec. 1 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines...
VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention...
STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/...
VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관
광고 없는 경험을 위해 가입하세요
지금 사용해 보세요
광고 유지